prolyl-phenylalanine | 3919-02-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: prolyl-phenylalanine
• 英文别名: Pro-Phe；3-Phenyl-2-[(pyrrolidinium-2-ylcarbonyl)amino]propanoate；3-phenyl-2-(pyrrolidin-1-ium-2-carbonylamino)propanoate
• CAS: 3919-02-6
• 化学式: C₁₄H₁₈N₂O₃
• 分子量: 262.309
• InChiKey: IWIANZLCJVYEFX-UHFFFAOYSA-N

物化性质

• 沸点：
  531.9±50.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Preparation of peptides with C-terminal proline amide
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0197794A2

  公开（公告）日：1986-10-15

  A peptide with C-terminal proline amide is produced by reacting in aqueous solution a protein substrate having C-terminal prolyl-leucine, prolyl-isoleucine, prolyl-valine, or polyl-phenylalanine with carboxypeptidase Y in the presence of amonia. The ammonia is preferably generated by the aqueous reaction of an ammonium salt and an alkali. An example of the peptide product is human calcitonin.

  在水溶液中，具有 C 端脯氨酰-亮氨酸、脯氨酰-异亮氨酸、脯氨酰-缬氨酸或多酰基苯丙氨酸的蛋白质底物与羧肽酶 Y 在氨的存在下发生反应，生成具有 C 端脯氨酸酰胺的多肽。 氨最好是由铵盐和碱在水溶液中反应生成的。 多肽产品的一个例子是人降钙素。
• Process for preparing peptides having a c-terminal proline amide
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0570244A1

  公开（公告）日：1993-11-18

  A process for the preparation of a peptide having a C-terminal amidated proline by the use of carboxypeptidase Y, and wherein only carboxypeptidase Y is used, even where a plurality of amino acids is attached to the proline of the precursor.

  一种利用羧基肽酶 Y 制备具有 C 端酰胺化脯氨酸的多肽的工艺，其中只使用了羧基肽酶 Y，即使在前体的脯氨酸上连接了多个氨基酸的情况下也是如此。
• E. COLI CAPABLE OF EXPRESSING CYTOCHROME P-450, AND BIOCONVERSION METHOD USING THE SAME
  申请人：MERCIAN CORPORATION

  公开号：EP2130916A1

  公开（公告）日：2009-12-09

  Disclosed is a means for improving the poor conversion efficiency in a bioconversion system using an Escherichia coli cell having a bacterium-originated cytochrome P-450 gene integrated therein. A recombinant Escherichia coli cell is produced by introducing aciB and aciC which encode a gene for the electron transport system originated from the Acinetobacter sp. OC4 strain into an Escherichia coli cell, and adding a polynucleotide encoding an N-terminal sequence composed of 48 amino acid residues of AciA and the like to the 5'-terminus of a bacterium-originated cytochrome P-450 gene, wherein AciA is an alkane-oxidative cytochrome P-450 originated from the Acinetobacter sp. OC4 strain. Use of the recombinant Escherichia coli cell results in much effective microbial conversion of a hydrophobic or amphipathic substrate compound into a desired compound.

  本发明公开了一种提高生物转化系统中低效转化率的方法，该方法使用的大肠杆菌细胞中整合了源于细菌的细胞色素 P-450 基因。重组大肠杆菌细胞是通过将编码源自醋杆菌 OC4 菌株的电子传递系统基因的 aciB 和 aciC 导入大肠杆菌细胞而产生的。OC4 菌株的电子传递系统基因的 aciB 和 aciC，并将编码由 AciA 等的 48 个氨基酸残基组成的 N 端序列的多核苷酸添加到源自细菌的细胞色素 P-450 基因的 5'- 末端，其中 AciA 是源自醋杆菌 OC4 菌株的烷氧化细胞色素 P-450。使用重组大肠杆菌细胞，可将疏水性或两性底物化合物有效地转化为所需化合物。
• Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
  申请人：Global Genomics Group, LLC

  公开号：US10254272B2

  公开（公告）日：2019-04-09

  The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.

  在某些方面，本发明涉及评估人体是否患有冠状动脉粥样硬化性疾病（ASCAD）或冠状动脉粥样硬化斑块的方法。在某些方面，本发明涉及用于诊断、分类、剖析和治疗动脉粥样硬化性冠状动脉疾病和或冠状动脉粥样硬化斑块的方法和试剂盒。
• Therapeutic administration of a modified alpha1 proteinase inhibitor
  申请人：——

  公开号：US20020004477A1

  公开（公告）日：2002-01-10

  A method for the treatment of asymtomatic HIV seropositive individuals to inhibit onset of an AIDS infection and, for suppression of propagation of HIV infections in individuals with a fully developed AIDS infection. The method consists of administering a therapeutic effective amount of a modified acute over (&agr;)} 1 Proteinase Inhibitor (macute over (&agr;)} 1 PI) to an individual within the effected population so as to inhibit and/or prevent acute over (&agr;)} PI facilitated HIV entry into healthy/uninfected cells.

  一种治疗无症状艾滋病毒血清反应阳性者的方法，以抑制艾滋病感染的发生，并抑制已完全发展为艾滋病感染者的艾滋病毒感染的传播。该方法包括施用治疗有效量的改良急性过(&agr;)}。 1 蛋白酶抑制剂 (macute over (&agr;)} 1) 1 PI），以抑制和/或防止急性过(&agr;)} 1蛋白酶抑制剂促进艾滋病毒进入健康/未感染细胞。